Are Computershare shares a buy after reaching new lows?

Brokers see modest to strong upside.

| More on:
Broker working with share prices on computers.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Computershare shares have fallen 16% over 6 months, as it navigates market volatility and interest rate uncertainties, impacting its core registry business and fee-based revenues.
  • As the global leader in share registry services, it benefits from scale and recurring fees, yet faces challenges from squeezed margins and muted M&A activity.
  • Analysts are divided: the most optimistic forecast suggests a 21% upside, while the average target is a more cautious with a modest 10% gain, reflecting mixed views on its near-term prospects. 

Computershare Ltd (ASX: CPU) shares have been on a roller-coaster this year. Once the darling of tech-focused financial stocks, the share price has gone from running red hot early this year to slipping into a steady decline towards fresh lows.

In the past 6 months Computershare shares have lost 16% of their value to $33.93 at the time of writing and they're 21.5% down from their year-high in February.

In 2025 the Computershare stock dropped 0.06%. To put it in context, the S&P/ASX 200 Index (ASX:XJO) rose 3.4% in the past 12 months.

Now for the big question, is the sell-off a buying opportunity or a structural stumble?

Trillion-dollar ledger keeper

First let's have a look at what the Melbourne based company does. At its core, Computershare is the behind-the-scenes backbone of the stock market. It manages share registries and related financial services for corporations around the world.

The $20 billion ASX company is essentially the global ledger keeper for trillions of dollars in financial assets, earning fees from corporate clients and transaction activity.

Computershare's strengths are its scale, high switching costs, recurring fee base and wide moat in registry services. It's the biggest player globally in what's essentially a niche oligopoly.

Squeezed margins, fewer mergers

But it's not without challenges. Computershare is heavily tied to the ebbs and flows of financial markets and interest rates, competitors and tech disruption.

Some analysts question how much further earnings can grow if margins are squeezed. Margin income is particularly vulnerable as rates ease, and slower merger and acquisitions activity can dampen high-margin transaction fees.

The flight of the shares

In most of 2025, Computershare shares looked like a classic compounder. The solid growth in recurring fee revenue, combined with share buybacks and a healthy dividend, propelled the stock higher.

But the market is telling a different story now with the Computershare shares in a steady decline. Some of this weakness reflects broader market headwinds.

Cautious sentiment crept into financial stocks as trading volumes in corporate actions softened and interest-rate uncertainty weighed on margin income.

What next for Computershare shares?

The broker community's views are mixed. Some upgrades have crept in, highlighting reasonable FY26 guidance and resilient revenue drivers.

However, price targets have been trimmed or flagged as full, suggesting limited near-term upside. On the other hand, strong FY25 results and a solid balance sheet hint that the business fundamentals remain intact.

The most positive analyst forecast has set a maximum 12-month price target of $41.08, which points to a 21% upside. However, most brokers are more conservative with an average 10% gain and a price target of $37.36 for the next 52 weeks.

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »